Research carried out at Oxford’s Nuffield Department of Clinical Neurosciences has led to the development of a new blood-based test to identify the pathology that triggers Parkinson’s disease before the main symptoms occur. This could allow clinicians to screen for those individuals at high risk of developing the disease and facilitate the timely introduction of precision therapies that are currently at clinical trial stage.
Parkinson’s disease starts more than ten years before patients come to the clinic with symptoms because their brain cells fail to handle a small protein called alpha-synuclein. This leads to the formation of abnormal clumps of alpha-synuclein which damage vulnerable nerve cells, causing the familiar movement disorder and often dementia. By the time people are diagnosed with Parkinson’s disease, most of these vulnerable nerve cells have already died and alpha-synuclein clumps have formed in many brain regions.
It would be useful if there was a way to predict whether the pathways that handle alpha-synuclein are impaired before the onset of Parkinson’s symptoms. This could help clinicians to identify people most likely to benefit from disease-modifying therapies when they become available.
In the paper, “Neuronally Derived Extracellular Vesicle α-Synuclein as a Serum Biomarker for Individuals at Risk of Developing Parkinson Disease” in JAMA Neurology, Shijun Yan and colleagues in the Tofaris lab revealed the promise of measuring a subtype of extracellular vesicles to identify changes in alpha-synuclein in people who are likely to develop Parkinson’s disease. Extracellular vesicles are nanoparticles that are released by all cell types and circulate in biofluids including blood, transporting molecular signals between cells.
Using an improved antibody-based assay developed by the research group, the test involves isolating those extracellular vesicles originating from nerve cells from blood, and then measuring their alpha-synuclein content. Professor George Tofaris explains, “A robust assay is crucial because neuronally-derived extracellular vesicles constitute less than 10% of all circulating vesicles, and ~99% of alpha-synuclein in blood is released from peripheral cells, mostly red blood cells.”
In the first study of its kind, the team looked at 365 at-risk individuals from four clinical cohorts (Oxford Discovery, Marburg, Cologne and the US-based Parkinson’s Progression Markers Initiative), 282 healthy controls and 71 people with genetic or sporadic Parkinson’s disease.
They found that those with the highest risk of developing Parkinson’s (more than 80% probability based on research criteria) had a two-fold increase in alpha-synuclein levels in neuronal extracellular vesicles and the test could accurately differentiate them from those with low risk (less than 5% probability) or healthy controls. Overall, the test could distinguish an individual with high risk of developing Parkinson’s from a healthy control with 90% probability.
These findings indicate that the blood test, together with a limited clinical assessment, could be used to screen and identify people who are at high risk of getting the disease. In further analysis, the test could also identify those who had evidence of neurodegeneration detected by imaging, or pathology detected by a spinal fluid assay, but had not yet developed a movement disorder or dementia.
In a small subgroup of 40 people who went on to develop Parkinson’s and related dementia, the blood test was positive in more than 80% of cases up to as much as seven years before the diagnosis.
In this group, there was a trend for higher levels of alpha-synuclein in neuronal extracellular vesicles in the blood to be associated with lower alpha-synuclein in the spinal fluid, and a longer interval before the onset of the main symptoms of Parkinson’s disease. This suggests that the nerve cells may protect themselves by packaging excess alpha-synuclein in extracellular vesicles which are then released in the blood.
The research builds on earlier findings by the Tofaris lab, also confirmed in the current study, showing that the biomarker is increased in patients with Parkinson’s disease but not in other Parkinson’s-like conditions.
The Tofaris lab, which is part of the Nuffield Department of Clinical Neurosciences and based in the Kavli Institute for Nanoscience Discovery, previously delineated the pathway which targets alpha-synuclein for destruction inside nerve cells. This pathway may also direct alpha-synuclein outside cells in extracellular vesicles, when intracellular protein turnover is inefficient in conditions such as aging and Parkinson’s disease.
Professor Tofaris said, “Collectively our studies demonstrate how fundamental investigations in alpha-synuclein biology can be translated into a biomarker for clinical application, in this case for the identification and stratification of Parkinson’s risk. A screening test that could be implemented at scale to identify the disease process early is imperative for the eventual instigation of targeted therapies as is currently done with screening programs for common types of cancer.”
More information: Shijun Yan et al, Neuronally Derived Extracellular Vesicle α-Synuclein as a Serum Biomarker for Individuals at Risk of Developing Parkinson Disease, JAMA Neurology (2023). DOI: 10.1001/jamaneurol.2023.4398
News
The Global Nanomedicine Market: Key Players and Emerging Technologies in Healthcare
This article provides an overview of the global nanomedicine market, highlighting key players, emerging technologies, and the challenges and opportunities that influence its growth and commercialization in the healthcare sector. Nanomedicines are nanotechnology-based drug products [...]
Scientists Have Discovered Toxic “Forever Chemicals” in Bottled Water
Scientists have found toxic PFAS in drinking water samples from around the world, with higher levels in tap water from China compared to the UK. Boiling water or using a filtration jug can reduce [...]
Urban Microbes Are Eating Disinfectants – Are We Fueling a New Health Threat?
New research reveals that microbes in urban environments are evolving to withstand the very cleaning agents designed to eliminate them. The study also uncovers new strains in Hong Kong, previously only found in the [...]
Startling Study Shows High-Potency Cannabis Alters DNA
The study shows that frequent use of high-potency cannabis alters DNA, affecting genes related to energy and immune function. These changes differ between those with and without psychosis, suggesting cannabis use could influence mental health through biological [...]
New nanotherapy targets artery inflammation in cardiovascular disease
Inflammation of the arteries is a primary precursor and driver of cardiovascular disease—the No. 1 killer of people in the United States. This inflammation is associated with the buildup of dangerous plaque inside the [...]
Revolutionary Nanoparticle Therapy for Prostate Cancer
A groundbreaking research effort involving teams from the University of Virginia, Mount Sinai, the University of Michigan, the University of Texas, and others has displayed the clinical efficacy of an innovative therapy that utilizes nanoparticles and [...]
Antibody engineering drives innovation in drug development
Monoclonal antibodies (mAbs) are used to prevent, detect, and treat a broad spectrum of non-communicable and communicable diseases. Over the past few years, the market for mAbs has grown exponentially with an expected compound [...]
Breakthrough Study Reveals How Bladder Cancer Starts and Spreads
Researchers found that DNA mutations from antiviral enzymes and chemotherapy fuel early bladder cancer, while abnormal circular DNA in tumor cells drives resistance to therapy. These discoveries open new therapeutic avenues. A groundbreaking study led by [...]
AI and Quantum Mechanics Accelerate Drug Discovery
A recent article published in the Journal of Chemical Information and Modeling researchers at Southern Methodist University (SMU) have developed SmartCADD, an open-source virtual tool designed to speed [...]
Targeting ‘undruggable’ diseases: Researchers reveal new levels of detail in targeted protein degradation
Researchers at the University of Dundee have revealed in the greatest detail yet the workings of molecules called protein degraders which can be deployed to combat what have previously been regarded as "undruggable" diseases, [...]
Revolutionizing Virology: AI Discovers Over 160,000 New RNA Viruses
Largest discovery of new virus species sheds light on the hidden virosphere. Artificial intelligence (AI) has been used to reveal details of a diverse and fundamental branch of life living right under our feet and in every [...]
Cardiac Crisis: COVID-19 Doubles Risk of Heart Attacks, Strokes, and Death
Research indicates that COVID-19 survivors face doubled risks of severe cardiac events for years after recovery, especially if hospitalized. People with A, B, or AB blood types are particularly vulnerable, highlighting the need for personalized approaches [...]
AI steps into science limelight with Nobel wins
For long periods of its history, artificial intelligence has lurked in the hinterland of science, often unloved and unfunded—but two Nobel prizes in one week suggest its time in the sunshine has finally arrived. [...]
MIT Scientists Shed New Light on the Critical Brain Connections That Define Consciousness
A new study provides further evidence that consciousness depends on communication between the brain’s sensory and cognitive regions in the cortex. Our brains are constantly making predictions about our surroundings, enabling us to focus [...]
Common Chemicals Found in Shampoo and Plastic Could Be Quietly Disrupting Your Heart’s Rhythm
UC study of Fernald data links environmental phenols to heart toxicities Environmental phenols are present in numerous everyday consumer products, serving as preservatives in packaged foods, parabens in shampoos, and bisphenol A (BPA) in [...]
Revolutionary Brain Tech Offers New Hope for Stroke and Injury Recovery
University of Pittsburgh researchers report that deep brain stimulation (DBS) can effectively enhance motor functions in individuals with arm and hand paralysis due to brain injuries, with promising results from early human and monkey [...]